These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 11967793)

  • 1. ACE inhibitors, angiotensin receptor antagonists and bradykinin.
    Schachter M
    J Renin Angiotensin Aldosterone Syst; 2000 Mar; 1(1):27-9. PubMed ID: 11967793
    [No Abstract]   [Full Text] [Related]  

  • 2. [Combination therapy with ACE inhibitors and angiotensin receptor antagonists].
    Kisters K
    Internist (Berl); 1999 Jun; 40(6):678-9. PubMed ID: 10420325
    [No Abstract]   [Full Text] [Related]  

  • 3. [ACE-inhibitors, AT1 receptor antagonists and diastolic dysfunction].
    Metra M; Nodari S; Bordonali T; Cagnazzi E; Boldi E; Dei Cas L
    Cardiologia; 1999 Dec; 44 Suppl 1(Pt 1):53-8. PubMed ID: 12497882
    [No Abstract]   [Full Text] [Related]  

  • 4. [Concurrence to ACE inhibitors? AT1 receptor blockers and hypertension].
    Heemann U; Kribben A; Phillip T
    Pharm Unserer Zeit; 2001; 30(4):309-12. PubMed ID: 11499256
    [No Abstract]   [Full Text] [Related]  

  • 5. Bradykinin contributes to the systemic hemodynamic effects of chronic angiotensin-converting enzyme inhibition in patients with heart failure.
    Cruden NL; Witherow FN; Webb DJ; Fox KA; Newby DE
    Arterioscler Thromb Vasc Biol; 2004 Jun; 24(6):1043-8. PubMed ID: 15105283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suppression of choroidal neovascularization by inhibiting angiotensin-converting enzyme: minimal role of bradykinin.
    Nagai N; Oike Y; Izumi-Nagai K; Koto T; Satofuka S; Shinoda H; Noda K; Ozawa Y; Inoue M; Tsubota K; Ishida S
    Invest Ophthalmol Vis Sci; 2007 May; 48(5):2321-6. PubMed ID: 17460297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Should angiotensin receptor blockers be added to angiotensin-converting enzyme inhibitors in the treatment of heart failure?
    Ghanem FA; Movahed A
    Rev Cardiovasc Med; 2005; 6(4):206-13. PubMed ID: 16379016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of polymorphisms of the renin-angiotensin system and bradykinin B2 receptor with ACE-inhibitor-related cough.
    Mukae S; Itoh S; Aoki S; Iwata T; Nishio K; Sato R; Katagiri T
    J Hum Hypertens; 2002 Dec; 16(12):857-63. PubMed ID: 12522467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of stroke and cancer: could angiotensin II type 1 receptor antagonists do better than angiotensin II converting enzyme inhibitors?
    Achard JM; Pruna A; Fernandez LA; Hottelart C; Mazouz H; Rosa A; Andrejak M; Fournier A
    Am J Hypertens; 1999 Oct; 12(10 Pt 1):1050-3. PubMed ID: 10560795
    [No Abstract]   [Full Text] [Related]  

  • 10. Are angiotensin-receptor blockers (ARBs) equivalent to or better than angiotensin-converting enzyme (ACE) inhibitors in the treatment of heart failure?
    Reigle J
    Crit Care Nurse; 2004 Dec; 24(6):67-9. PubMed ID: 15646090
    [No Abstract]   [Full Text] [Related]  

  • 11. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in hypertension due to primary aldosteronism: a case for exclusion.
    Bubbar CD; Blackburn DF; Wilson MP; Wilson TW
    Ann Pharmacother; 2007 Jan; 41(1):129-32. PubMed ID: 17179189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic controversies in hypertension management: angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers for diabetic nephropathy? A case for ACE inhibitors.
    Crook ED; Preddie DC
    Ethn Dis; 2002; 12(4):S3-49-52. PubMed ID: 12477155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pathophysiological and clinical implications of AT(1) and AT(2) angiotensin II receptors in essential hypertension].
    Burnier M
    Drugs; 2002; 62 Spec No 1():21-9. PubMed ID: 12036386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New therapeutic approaches in primary IgA nephropathy.
    Locatelli F; Pozzi C; Del Vecchio L; Andrulli S; Bolasco P; Fogazzi G; Altieri P; Ponticelli C
    Adv Nephrol Necker Hosp; 1999; 29():73-91. PubMed ID: 10561738
    [No Abstract]   [Full Text] [Related]  

  • 15. 'ACE inhibitors are better than AT(1) receptor blockers (ARBs)' - controversies in heart failure.
    White HL; Hall AS
    Eur J Heart Fail; 2000 Sep; 2(3):237-40. PubMed ID: 10938482
    [No Abstract]   [Full Text] [Related]  

  • 16. Distinct time courses of renal protective action of angiotensin receptor antagonists and ACE inhibitors in chronic renal disease.
    Matsuda H; Hayashi K; Saruta T
    J Hum Hypertens; 2003 Apr; 17(4):271-6. PubMed ID: 12692572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Angiotensin receptor blocker often a valuable alternative to ACE inhibitors].
    Partanen J
    Duodecim; 2003; 119(13):1193-6. PubMed ID: 12908180
    [No Abstract]   [Full Text] [Related]  

  • 18. AT(1)-receptor blockade and the kidney: importance of non-ACE pathways in health and disease.
    Hollenberg NK
    J Hum Hypertens; 2002 Aug; 16 Suppl 3():S59-63. PubMed ID: 12140730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ACE inhibitors versus angiotensin receptor blockers in diabetic nephropathy: is there a winner?
    Lewis EJ; Lewis JB
    J Am Soc Nephrol; 2004 May; 15(5):1358-60. PubMed ID: 15100380
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparison of the effects of angiotensin receptor antagonist, angiotensin converting enzyme inhibitor, and their combination on regression of left ventricular hypertrophy of diabetes type 2 patients on recent onset hemodialysis therapy.
    Suzuki H; Kanno Y; Kaneko K; Kaneko M; Kotaki S; Mimura T; Takane H
    Ther Apher Dial; 2004 Aug; 8(4):320-7. PubMed ID: 15274684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.